CATX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CATX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-06), the Trailing Annual Dividend Yield of Perspective Therapeutics is 0.00%.
The historical rank and industry rank for Perspective Therapeutics's Dividend Yield % or its related term are showing as below:
Perspective Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00.
As of today (2024-05-06), the Forward Dividend Yield % of Perspective Therapeutics is 0.00%.
Perspective Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
The historical data trend for Perspective Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Dec23 | |||||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Perspective Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Devices subindustry, Perspective Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Perspective Therapeutics's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Perspective Therapeutics (AMEX:CATX) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Perspective Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Williamson Robert F Iii | director | 140 LASALLE AVENUE, PIEDMONT CA 94610 |
Markus Puhlmann | officer: Chief Medical Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Jonathan Robert Hunt | officer: Chief Financial Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Lori A Woods | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Heidi Henson | director | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
Frank Morich | director | 40 GUEST STREET, BOSTON MA 02135 |
Johan M. Spoor | director, officer: CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Mark John Austin | officer: Controller/Prin Fin&Acct Offic | 350 HILLS ST, STE 106, RICHLAND WA 99354 |
Philip J Vitale | director | 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255 |
Michael W Mccormick | director | 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260 |
William Cavanagh | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Alan Hoffmann | director | 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032 |
Michael Krachon | officer: VP of Sales & Marketing | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Krista Cline | officer: Dir. of Operations, Secretary | 350 HILLS STREET, STE 106, RICHLAND WA 99354 |
Jennifer Streeter | officer: VP of Human Resources | 350 HILLS STREET SUITE 106, RICHLAND WA 99354 |
From GuruFocus
By Marketwired Marketwired • 10-24-2018
By Marketwired Marketwired • 07-12-2018
By Value_Insider Value_Insider • 10-16-2022
By Value_Insider Value_Insider • 11-13-2022
By Marketwired Marketwired • 09-10-2018
By PRNewswire PRNewswire • 01-07-2021
By Marketwired Marketwired • 12-03-2018
By ACCESSWIRE AccessWire • 04-12-2019
By Marketwired Marketwired • 06-12-2019
By Marketwired Marketwired • 09-12-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.